Diagnosis & Disease Information

stethoscope money

Outcomes-Based Pricing Doesn’t Cut Costs of PCSK9 Inhibitors

“Although outcomes-based pricing may have a role in other settings, our analysis of its application to PCSK9 inhibitors – effective preventive medications with a high price tag – shows the potential limitation of this approach for high-cost preventive therapies,” the authors write.